Literatur für onkologie heute 9/2020

SCHWERPUNKT: IMMUNONKOLOGIE, KOPF-HALS-TUMOREN

Systemische Erstlinien- und Sequenztherapie des metastasierten Urothelkarzinoms (S. 26–29)

G. Niegisch

13. Powles et al. LBA 1, ASCO 2020

Aktuelle Therapieaspekte des Plattenepithelkarzinoms im Kopf-Hals-Bereich (S. 38–44)

J. Doescher, M. Brand und T. K. Hoffmann


15. Bejar R et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: Analysis of combined data sets from the International Working Group for Prognosis on MDS-molecular Committee. Blood. 2015; 126(23): 907
18. Germing U et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes. Leukemia 2005; 19(12): 2223–2231
22. Silzle T et al. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. Blood Cancer J. 2019; 9(8): 63
23. Zipperer E et al: The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica. 2014; 99(3): 31–32
37. Steensma DP et al. Imetelstat treatment leads to durable transfusion independence (TI) in RBC transfusion-dependent (TD), non-Del(5q) lower risk MDS relapsed/refractory to erythropoiesis-stimulating agent (ESA) who are lenalidomide (LEN) and HMA naive. Blood 2018; 132(Suppl. 1): 463


